Related Experiment Video
Updated: Apr 19, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
14.8K
Melatonin treatment improves primary progressive multiple sclerosis: a case report.
Antonio López-González1, Nuria Álvarez-Sánchez, Patricia J Lardone
1Department of Neurosurgery, Virgen Macarena & Virgen del Rocío University Hospitals, Seville, Spain.
Journal of Pineal Research
|December 30, 2014
Summary
A patient with primary progressive multiple sclerosis (PPMS) experienced significant recovery in mobility after taking melatonin. This suggests melatonin may offer therapeutic benefits for PPMS patients with severe disability.
Area of Science:
- Neuroscience
- Endocrinology
Background:
- Primary progressive multiple sclerosis (PPMS) is a debilitating neurodegenerative disease.
- Current treatments for PPMS have limited efficacy in halting disease progression.
Observation:
- A 28-year-old female diagnosed with PPMS showed disease progression over 9 years despite glucocorticoid treatment, reaching an Expanded Disability Status Scale (EDSS) of 8.0.
- The patient initiated melatonin therapy (50-300 mg/day) as her sole treatment.
Findings:
- Over 4 years of melatonin treatment, the patient's EDSS score improved to 6.0, indicating substantial recovery of motor function.
- This improvement correlated temporally with melatonin initiation and demonstrated long-lasting effects.
Implications:
- Melatonin may represent a novel therapeutic agent for managing primary progressive multiple sclerosis.
- Further research is warranted to explore the neuroprotective and restorative mechanisms of melatonin in neurodegenerative conditions.
Related Concept Videos
01:19Management of Insomnia
805
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
805
01:19Multiple Sclerosis l: Introduction
2
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
2
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:07Narcolepsy
831
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
831
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
944
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
944